Mr PL was administered Drug A that acts on a particular receptor. Unfortunately, it was given in overdose and produced an adverse effect. Drug B is then administered which blocks that receptor. The effect of drug B results in a reduction in the effect of drug A. Comment on if Drug B is acting competitively (reversibly) or non-competitively (irreversibly)? Provide one suitable clinically relevant example of such interaction.

From the Hill Plot below, the of the first binding event for the receptor-ligand system under study is: Q1 4nM Ο 10 μΜ -2 nM 2 nM Calculate the Hill Coefficient from the receptor-ligand binding data below: Q2 4 100 2 3 (0-1) 60 log 10 8 6 4 2 0 -2 -4 -6 -6 -4 -2 0 2 4 log [L] (nM) 6 8 10

Select only one of these types of GPCR and describe the signal transduction that is involved in that receptor.

Psilocybin is rapidly de-phosphorylated in the body into psilocin, which is anagonist For the 5-HT 24 Serotonin receptor, which binds the neurotransmitter serotonin as its natural ligand, and acts as a ligand-gated ion channel in the central nervous system. НО. Serotonin NH₂

A consumer survey has highlighted a major increase in the use of Pregabalin, an authorised antiepileptic drug. The working hypothesis is that this drug is being used in other pathologies, such as to treat neuropathic pain. What sort of indicators could we use to obtain information that might enable us to test this hypothesis? Select one: O a. The conducting of a controlled clinical trial enabling us to assess the efficacy of Pregabalin in neuropathic pain. O b. The construction of drug-indication indicators (studying consumption in terms of the indication for which it is prescribed). O c. The construction of indicators that relate the drug to the indication and the treatment outcome. O d. A comparison between the consumption of Pregabalin in defined daily doses per 1000 inhabitants per day and the diagnosed prevalence of epilepsy.

Describe the process and results of receptor-ligand binding.

Describe the features of competitive receptor antagonism.

you have been asked to develop a drug that could inhibit an enzyme linked receptor. what are the potential pharmacological targets you could design your drug to interact with. which one should you choose and why

5.. A sample of cells has a total receptor concentration of 25 mM. Ninety percent of the receptors have bound ligand and the concentration of free ligand is 125 µM. Calculate the K for the receptor ligand interaction. (a) What is the AG° for binding for this interaction at 25°C?

What causes NMDA receptors to open? Glutamate binding and depolarization of the membrane Glutamate binding O Depolarization of the membrane O GABA binding